Evaluation of heterogeneous factors of low-grade prostate cancer in patients before and after radical prostatectomy

被引:0
|
作者
Veliev, E., I [1 ,2 ]
Goncharuk, D. A. [1 ]
Sokolov, E. A. [1 ,2 ]
Ivkin, E., V [2 ]
Paklina, O., V [2 ]
Setdikova, G. R. [2 ]
机构
[1] Russian Med Acad Continuing Profess Educ, Minist Hlth Russia, Build 1,2-1 Barrikadnaya St, Moscow 125993, Russia
[2] SP Botkin City Clin Hosp, Moscow Healthcare Dept, 52nd Botkinskiy Proezd, Moscow 125284, Russia
来源
ONKOUROLOGIYA | 2020年 / 16卷 / 03期
关键词
prostate cancer; prostate specific antigen kinetics; prostate biopsy; biochemical recurrence; ANTIGEN VELOCITY; GLEASON SCORE; ACTIVE SURVEILLANCE; DOUBLING TIME; RISK; MEN; RECURRENCE; GUIDELINES;
D O I
10.17650/1726-9776-2020-16-3-70-79
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: to determine the degree of heterogeneity of prastate cancer Gleason 6 (3 + 3) by assessing: long-term ontological results, mismatch of pre- and postoperative degree of prastate cancer aggressiveness, preoperative clinical component. Materials and methods. 528 patients with clinically localized prostate cancer and Gleasonos preoperative score of 6 (3 + 3). All patients were divided into 3 groups: group 1(n =151) - Gleason 6, prostate specific antigen (PSA) density <0.15 ng/ml/cm(3), <= 4 positive biopsy cores, <50 % lesion of the biopsy cores, group 2 (n = 229) - Gleason 6, PSA <10 ng/ml and group 3 (n =148) - Gleason 6, PSA >10 ng/ml. Results. Statistically significant differences between group 1 and group 2 were observed only when assessing PSA velocity (p <0.017). The median time to the development of biochemical relapse (BCR) in the study population was 12 (3-77) months. BCR in group 1 was observed in 1.98 % of patients, in group 2 and 3 - 786 and 14.19 %, respectively. Statistically significant differences in the time of onset of BCR within 2 years after surgery were found between groups 1 and 2 (p = 0.002) and group I and 3 (p = 0.0001). An increase in the degree of malignancy after surgery in group 1 was determined only in 13 % of patients, in group 2 in 27 %, in group 3 in 43 % of patients. The contribution of a greater postoperative degree of malignancy of prostate cancer to the development of BCR in group 1 was 1.32 % (2 out of 3 patients). Thus, in group 1 in the case of true Gleason 6 (3 + 3), the probability of BCR was 0.66 %. Conclusion. PSA velocity before surgery showed a statistical difference between groups 1 and 2. Based on long-term ontological results after surgery, heterogeneous behavior of the tumor is observed among the study groups. Group 1 in comparison with group 2 and 3 showed the lowest frequency of increase in the Gleason score and the likelihood of developing BCR after surgery. These results may be useful in planning an individual patient treatment plan.
引用
收藏
页码:70 / 79
页数:10
相关论文
共 50 条
  • [1] Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer
    Sanguedolce, Francesca
    Falagario, Ugo Giovanni
    Castellan, Pietro
    Di Nauta, Michele
    Silecchia, Giovanni
    Bruno, Salvatore M.
    Russo, Davide
    Treacy, Patrick-Julien
    Tewari, Ashutosh K.
    Montironi, Rodolfo
    Carrieri, Giuseppe
    Cormio, Luigi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (10) : 793.e19 - 793.e25
  • [2] Risk Factors of Patients with Prostate Cancer Upgrading for International Society of Urological Pathology Grade Group 1 After Radical Prostatectomy
    Ozgur, Abdurrahman
    Ozgur, Gunal
    Sahin, Bahadir
    Filinte, Deniz
    Tinay, Ilker
    cam, Haydar Kamil
    Turkeri, Levent
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2022, 21 (01): : 10 - 13
  • [3] Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer
    Khaja, Azharuddin Sajid Syed
    Egevad, Lars
    Helczynski, Leszek
    Wiklund, Peter
    Andersson, Tommy
    Bjartell, Anders
    CANCER MEDICINE, 2012, 1 (01): : 96 - 104
  • [4] The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer
    Gandaglia, Giorgio
    Cozzarini, Cesare
    Mottrie, Alexandre
    Bossi, Alberto
    Fossati, Nicola
    Montorsi, Francesco
    Briganti, Alberto
    CURRENT ONCOLOGY REPORTS, 2015, 17 (12)
  • [5] Factors affecting biochemical recurrence of prostate cancer after radical prostatectomy in patients with positive and negative surgical margin
    Celik, Serdar
    Eker, Anil
    Bozkurt, Ibrahim Halil
    Bolat, Deniz
    Basmaci, Ismail
    Sefik, Ertugrul
    Degirmenci, Tansu
    Gunlusoy, Bulent
    PROSTATE INTERNATIONAL, 2020, 8 (04) : 178 - 184
  • [6] Efficacy of radical prostatectomy on prostate cancer patients and analysis of risk factors for biochemical recurrence after radical prostatectomy
    Yang, Xinping
    Shi, Yuanyuan
    Lin, Yang
    Tian, Yuxin
    JOURNAL OF BUON, 2020, 25 (06): : 2623 - 2628
  • [7] Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer
    Flood, Trevor A.
    Schieda, Nicola
    Sim, Jordan
    Breau, Rodney H.
    Morash, Chris
    Belanger, Eric C.
    Robertson, Susan J.
    VIRCHOWS ARCHIV, 2018, 472 (02) : 205 - 212
  • [8] Evaluation of tumor morphologies and association with biochemical recurrence after radical prostatectomy in grade group 5 prostate cancer
    Trevor A. Flood
    Nicola Schieda
    Jordan Sim
    Rodney H. Breau
    Chris Morash
    Eric C. Belanger
    Susan J. Robertson
    Virchows Archiv, 2018, 472 : 205 - 212
  • [9] Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients
    Gandaglia, Giorgio
    Briganti, Alberto
    Clarke, Noel
    Karnes, R. Jeffrey
    Graefen, Markus
    Ost, Piet
    Zietman, Anthony Laurence
    Roach, Mack, III
    EUROPEAN UROLOGY, 2017, 72 (05) : 689 - 709
  • [10] Racial disparities in mortality for patients with prostate cancer after radical prostatectomy
    Wen, Wanqing
    Luckenbaugh, Amy N.
    Bayley, Christina E.
    Pension, David F.
    Shu, Xiao-Ou
    CANCER, 2021, 127 (09) : 1517 - 1528